Welcome to our dedicated page for Traws Pharma news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule drug candidates aimed at treating cancer. Utilizing a proprietary chemistry platform, Onconova has developed an extensive library of targeted anti-cancer agents designed to interfere with specific cellular pathways critical to cancer cells while minimizing harm to normal cells.
The company's core business is centered on three key product candidates currently in clinical trials and six active pre-clinical programs. These innovative treatments aim to improve patient outcomes by directly addressing the disease, reducing recurrence, and lessening the side effects commonly associated with existing therapies.
Among its recent achievements, Onconova has made significant strides in translational science to better understand the pathways affected by its lead drug candidate, rigosertib. This research is expected to guide future clinical studies and combination treatments for challenging cancer types.
Onconova regularly hosts conference calls and webcasts to update stakeholders on its progress. For instance, the company is scheduled to hold a conference call and webcast on November 14, 2023, to provide further insights into its ongoing projects and recent developments.
Onconova Therapeutics (NASDAQ: ONTX) reported financial results for 2021, showing a net loss of $16.2 million or $0.96 per share, an improvement from a $25.2 million loss in 2020. Cash reserves increased to $55.1 million, expected to fund operations for at least two more years. Ongoing Phase 1 trials of narazaciclib in the U.S. and China are progressing well, with no dose-limiting toxicities. The company also highlights promising data from rigosertib trials. Management is optimistic about future developments in 2022, particularly in identifying a recommended Phase 2 dose for narazaciclib.
Onconova Therapeutics (NASDAQ: ONTX) will release its Q4 and full year 2021 financial results on March 17, 2022, hosting a conference call at 4:30 p.m. ET to discuss the results and pipeline updates. The company specializes in developing novel anti-cancer therapies, including narazaciclib and rigosertib, currently in clinical trials in the US and China. Detailed information on participation for the call is available on their website. Future prospects depend on the success of their clinical trials, which are subject to risks and uncertainties.
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on cancer treatment, will participate in the Guggenheim Oncology Conference from February 9-11, 2022. CEO Steven Fruchtman will present a fireside chat on February 10 at 8:30 a.m. ET, available via webcast. Following the presentation, a replay will be archived on Onconova's website. The company will also hold 1x1 meetings on February 9-10, exclusively arranged through Guggenheim. Onconova specializes in developing targeted anti-cancer agents, including the multi-kinase inhibitor narazaciclib and rigosertib for specific cancers.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) will participate in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10 to January 13, 2022. A corporate overview by CEO Steven Fruchtman will be available on-demand starting January 10, 2022, at 7:00 a.m. ET, and can be accessed on the Onconova website for 90 days. The company focuses on innovative therapies for cancer treatment, including its multi-kinase inhibitor narazaciclib and rigosertib for KRAS+ non-small cell lung cancer.
Onconova Therapeutics (NASDAQ: ONTX) announced the appointment of Dr. Adar Makovski Silverstein as Director of Corporate Development. Dr. Silverstein brings significant expertise in oncology and business development, having previously worked at Amgen. The company is optimistic about its pipeline, including narazaciclib, which shows potential across multiple indications, and rigosertib, currently in an investigator-initiated trial for KRAS+ non-small cell lung cancer. President Dr. Steven M. Fruchtman highlighted her scientific background as valuable for advancing their innovative therapies.
Onconova Therapeutics announced preliminary data from an investigator-initiated Phase 2 trial of rigosertib monotherapy in a 24-year-old patient with advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC). The patient achieved a sustained complete response after 13 treatment cycles without signs of metastatic disease. Rigosertib has demonstrated efficacy against aggressive tumor cells in RDEB, which presents a high unmet medical need. The trial continues with hopes to enroll additional patients in multiple locations.
Onconova Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: ONTX), will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. An on-demand corporate overview by President & CEO Steven Fruchtman will be available starting November 22, 2021, at 10:00 a.m. ET. Registered attendees can access the presentation until December 2, 2021. Additionally, Onconova will engage in 1x1 meetings from November 30 to December 2, 2021, requested exclusively through Piper Sandler.
Onconova focuses on novel cancer therapies, including narazaciclib and rigosertib.
Onconova Therapeutics (NASDAQ: ONTX) reported its third-quarter financial results for 2021, highlighting significant clinical advancements. The ongoing Phase 1 studies of narazaciclib showed no dose-limiting toxicities, while promising results emerged from the rigosertib combination trial in KRAS+ non-small cell lung cancer, with 29% objective response rate. The company secured $21 million from a public offering, improving financial stability. As of September 30, 2021, cash reserves were $59.4 million, sufficient to support operations for over two years. The net loss for the quarter narrowed to $3.5 million.
Onconova Therapeutics will release its third-quarter 2021 financial results on November 11, 2021, followed by a conference call at 4:30 p.m. ET. The call will provide insights on the company's financial performance and pipeline updates.
The clinical-stage biopharmaceutical company focuses on novel cancer treatments, including narazaciclib and rigosertib. Both products are currently in various study phases aimed at improving cancer care. Investors can access the call via phone or listen online.
Onconova Therapeutics (NASDAQ: ONTX) announced participation in the Sachs 21st Annual Biotech in Europe Forum on October 7-8, 2021. Management will be available for 1x1 meetings from October 4-8, 2021, via the Sachs Event portal.
Onconova is focused on developing novel cancer treatments, including the multi-kinase inhibitor ON 123300 in Phase 1 studies in the U.S. and China. Additionally, rigosertib is being explored in a combo treatment for KRAS+ non-small cell lung cancer.
FAQ
What is the market cap of Traws Pharma (ONTX)?
What does Onconova Therapeutics, Inc. specialize in?
What are the key product candidates of Onconova Therapeutics?
What recent achievements has Onconova made?
When is the next conference call scheduled?
How does Onconova's proprietary chemistry platform benefit cancer treatment?
What is Onconova's approach to improving cancer treatment outcomes?
How does Onconova keep stakeholders informed about its progress?
What is the significance of rigosertib in Onconova's research?
How can interested parties participate in Onconova's conference calls?
What is the trading symbol for Onconova Therapeutics, Inc.?
